6 assets in Griscelli Syndrome

Therapeutic assets addressing Griscelli Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Griscelli Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Busulfanum Griscelli Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide Griscelli Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Fludarabine Griscelli Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Melphalan Griscelli Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Griscelli Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)